adjuvanted trivalent subunit influenza vaccine

An adjuvanted trivalent subunit influenza vaccine is an inactivated flu vaccine containing highly purified surface antigens (subunits) from three different influenza virus strains—one A(H1N1), one A(H3N2), and one B/Victoria lineage virus. The "adjuvanted" component refers to the inclusion of MF59, an oil-in-water emulsion based on squalene, which enhances the immune response to the viral antigens. This formulation is designed primarily for older adults (65 years and above) who may have a weaker immune response to standard vaccines. The addition of MF59 broadens and strengthens immunity, potentially offering better protection against severe outcomes like hospitalization compared to non-adjuvanted vaccines. The most widely used brand is Fluad, developed by Seqirus (a CSL company). This type of vaccine has been approved and used extensively in Europe since 1997 and in North America since 2011[1][3][4].

Brand names

Fluad

Other names

aTIVMF59-adjuvanted trivalent influenza vaccineMF-59-adjuvanted trivalent influenza vaccineMF 59-adjuvanted trivalent influenza vaccineMF59-adjuvanted TIVMF-59-adjuvanted TIVMF 59-adjuvanted TIV